Proviral HTV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy

M. Birk, S. Aleman, U. Visco-Comandini, A. Sonnerborg

Research output: Contribution to journalArticle

Abstract

Objectives Different experimental approaches have shown that, despite plasma viral loads under the threshold of detection, HIV-1 frequently continues to replicate in patients receiving potent antiretroviral therapy. However, whether this low-grade viral replication is sufficient for the generation of new major quasispecies has not been studied. Thus, in order to evaluate the extent of variation in the major proviral HIV-1 population, we monitored proviral DNA sequences in such patients over a time period of up to 30 months. Methods DNA was extracted from peripheral blood mononuclear cells (PBMC) and the V3 region was amplified by nested polymerase chain reaction (PCR) and directly sequenced. Additionally, both HIV-1 RNA and DNA levels and CD4+T-lymphocyte counts were monitored. Results Analysing the V3 gene sequences of 17 patients, we observed a sequence evolution in nine patients. Interestingly, the majority of these changes (77%) occurred in the first interval following the initiation of therapy and despite signs of ongoing replication the proviral DNA levels continued to decrease in all patients. Conclusions Our data suggest that, although available data report that HIV-1 continues to replicate in patients with undetectable viraemia, the extent of viral replication in many of these patients is not sufficient to result in changes in the major viral population.

Original languageEnglish
Pages (from-to)205-211
Number of pages7
JournalHIV Medicine
Volume1
Issue number4
Publication statusPublished - 2000

Keywords

  • Antiretroviral therapy
  • HIV-1 DNA
  • HIV-1 RNA
  • Viral evolution

ASJC Scopus subject areas

  • Virology
  • Medicine(all)
  • Immunology

Fingerprint Dive into the research topics of 'Proviral HTV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy'. Together they form a unique fingerprint.

  • Cite this